Clinical Trial Update: A Phase 1B Study of Canakinumab, Spartalizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic Cancer (PC) Patients [Phase 1]

View source ↗

Summary

Phase 1B trial evaluating a quadruple combo of canakinumab, spartalizumab, nab-paclitaxel, and gemcitabine in metastatic pancreatic ductal adenocarcinoma; the s…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Ductal Adenocarcinoma

Drugs mentioned

• Abraxane (paclitaxel albumin-bound)
• Gemzar (gemcitabine)
• ILARIS (canakinumab)
• Spartalizumab (spartalizumab)

Snippet

Sponsor: Pancreatic Cancer Action Network | Conditions: Metastatic Pancreatic Ductal Adenocarcinoma | Phase 1 | Status: COMPLETED | Results posted: 2025-04-08